ACE2 and neoplasm: Tissues with VE-cadherin+/VM+ in TMA were reviewed, then 2/7 of patients in ACE2 low expressing group and 8/18 of patients in ACE2 high expressing group were found to be expressing VE-cadherin on membrane of tumor cells (Figure 6H).